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Resum
Biocompatibilitat, biodistribució, biodegradació, inflamació i in-
terferència amb el funcionament normal de les cèl·lules i teixits, 
entre d’altres, determinarà la toxicitat de les nanopartícules in-
orgàniques i nanoestructures de carbó, i per tant l’extensió del 
seu us. Exemples recents a la literatura científica mostren que 
les nanopartícules inorgàniques i els nanotubs de carboni no 
causen efectes tòxics aguts. De totes maneres, la interacció 
d’aquests materials amb organismes vius pot pertorbar la seva 
activitat normal induint funcionaments erronis i malalties. De 
fet, les interaccions entre nanopartícules i biologia que s’han 
observat, que poden ser usades per detectar i manipular es-
tats biològics i contribuir a una millor diagnosis i teràpia, també 
podrien tenir un impacte negatiu en la salut i el medi ambient si 
s’alliberen incontroladament quantitats massives d’alguns ti-
pus de nanopartícules, abans que es faci una avaluació ex-
haustiva dels riscos potencials d’aquests nous materials. La 
pregunta clau és si els riscos desconeguts de les nanoparticu-
les, en particular el seu impacte en la salut i el medi ambient, 
supera els beneficis d’aquesta tecnologia en societat. Per això, 
pel futur desenvolupament de la nanotecnologia, l’avaluació de 
la seva potencial toxicitat es clau. 
Paraules clau: nanopartícules · toxicologia · 
biodistribució
Abstract
Biocompatibility, biodistribution, biodegradation, inflammation 
and interference with the normal functioning of cells and tis-
sues are some of the features that determine the toxicity of en-
gineered inorganic nanoparticles and carbon nanostructures, 
and therefore the potential extent of their use. Recent exam-
ples in the literature show that engineered inorganic nanoparti-
cles and carbon nanostructures do not normally cause acute 
toxic effects. However, their interaction with living organisms 
may disrupt normal activity leading to disordersand disease. 
Nanoparticle-organism interactions, which can be used to de-
tect and manipulate biological states and to heal damaged or-
gans in an environment controlled by specialists, as in clinical 
cases, could lead to environmental and human health hazards 
if nanoparticles are released prior to adequate risk assessment 
and without proper controls. The central question is whether 
the unknown risks of engineered nanoparticles, in particular 
their impact on health and the environment, outweigh their es-
tablished benefits for society. Therefore, to accurately evaluate 
the utility of these materials it is necessary to assess their po-
tential toxicity.




As society begins to use nanomaterials in greater quantities 
and in consumer products, interest in the broader implications 
of this emerging technology has grown together with unfound-
ed “nanoeuphoria” and “nanoscares”. The central question is 
whether the unknown risks of engineered nanoparticles (NP), in 
particular their impact on health and the environment, outweigh 
their established benefits for society [1]. Therefore, for any ap-
plication and future developments, a key issue is to accurately 
evaluate the utility of these materials and it is necessary to as-
sess their potential toxicity —whether due to their inherent 
chemical composition (e.g., reactive metals [2]), their physical 
size (e.g., Au55 attaching to DNA [3]), their large and accessi-
ble inorganic surfaces (e.g., TiO2 NP versus microparticles [4]) 
or as a consequence of their particular nanoscale characteris-
tics (e.g., carbon nanotubes that have reached the lungs ap-
pear significantly more toxic than carbon black and graphite 
[5,6]). While there is a significant body of research on the ef-
fects of natural and incidental NP —those that occur as unin-
tentional byproducts of other processes, such as combus-
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tion— only a few engineered nanomaterials have been studied 
in this way. In fact, some incidental NP are central to many nat-
ural processes, from marine aerosols [7] to volcanoes and for-
est fires [8-12], and they do not have a great effect on health 
[13]. Thus, it has been observed that nanomaterials, including 
fullerenes, are produced naturally in combustion processes, 
while burning paraffin and diesel produces carbon nanotubes 
(CNT) [14]. Nanomaterials can also be found perfectly integrat-
ed into biological structures. For example, biogenic magnetic 
NP occur naturally in many organisms ranging from bacteria 
through protozoa to animals [15,16]. A biological model of 
coated nanomaterials also found in humans is ferritin, which is 
an iron storage protein, approximately 12-nm in diameter, that 
contains 5- to 7-nm-sized hydrous ferric oxide inside a protec-
tive protein shell [17,18]. Obvious differences between natural, 
unintentional NP and intentional, anthropogenic NP are: i) the 
polydisperse and chemically complex nature of the former 
[19,20] in contrast to the monodisperse and precise chemically 
engineered characteristics of the latter, and ii) particle morphol-
ogy (often a branched structure from combustion particles ver-
sus spherical forms of engineered NPs, although other shapes, 
such as tubes, wires, rings and disks, are also manufactured). 
Despite these differences, the same toxicological principles are 
likely to apply for both types of NP.
If nanomaterials have received enormous attention it is be-
cause of their potential interaction with living systems [21,22]. 
This gives rise to potential applications in biology and medicine, 
due to their ability to detect the state of biological systems and 
living organisms optically, electrically and magnetically, thanks 
to recent developments in materials physics and chemistry [23]. 
Thus, NP can be designed with different properties, such as 
fluorescence or possessing a magnetic moment [24,25], and 
these properties can be harnessed and used as local nano-
probes or nano-manipulators in biological and medical applica-
tions (e.g.: fluorescence labeling of cellular compartments [24]; 
the use of fluorescent or magnetic particles as contrast agents; 
magnetic separation [26]; and targeted drug delivery [27]). Deri-
vatization of NP with biological molecules has successfully been 
applied in materials science and biological research in recent 
years. Conjugates of NP biopolymers (like proteins or DNA) 
show great promise in both fields: biological diagnostics, where 
NP can provide unique detection signatures; and nanotechnol-
ogy, where the information content of biomolecules can be har-
nessed for the spatial patterning of NP. There are many strate-
gies available for bioconjugation of NP, including attachment to 
elastin [28], antisenses [29], biotin-avidin [24], antigen-antibod-
ies [30], peptides [31], proteins [32], etc. 
Thus, the characteristic biokinetic behavior of NP promises 
applications in diagnostic and therapeutic devices, and in tools 
to investigate and understand molecular processes and struc-
tures in living cells [33-36]. However, precisely this unique bi-
okinetic behavior of NPs (cellular endocytosis, transcytosis, 
neuronal, lymphatic and circulatory translocation and distribu-
tion, etc.) which makes them so attractive for medical applica-
tions, may be associated with potential toxicity. Not only bacte-
ria, viruses and parasites, but also inorganic foreign bodies can 
be the cause of various pathologies: silicosis, asbestosis and 
inflammatory reactions to the debris from worn out prostheses 
or related to diesel exhaust fumes [37] are only a few among 
many possible examples. Thus, for example, NP-facilitated 
drug delivery to the central nervous system (CNS) raises the 
question of the fate of the NP after their translocation to spe-
cific cell types or to sub-cellular structures in the brain. 
2.	 Nanoparticles	before	nanotechnology
Although humans have been exposed to airborne NP of natural 
origin throughout our evolution, such exposure has increased 
dramatically over the last century due to anthropogenic sourc-
es, such as internal combustion engines, power plants, and 
many other sources of thermodegradation. Similarly, we have 
been in contact with man-made inorganic NP for some time. A 
well-known case is the use of NP as pigments since ancient 
Roman times, as in the Lycurgus cup, or in cosmetic oint-
ments. It has been claimedthat lead-based chemistry involving 
the combination of naturally available minerals with oils, various 
creams, or water, which was initiated in Egypt more than 4000 
years ago, could have resulted in the synthesis of lead sulfide 
(PbS) NP with a diameter of about 5 nm. These crystals appear 
quite similar to PbS quantum dots synthesized in modern ma-
terials science techniques [38]. Another case is the observation 
of TiO2 NP in the lungs (in the alveoli) of the Oetzi man (5,400 
years old) [39]. It is believed that TiO2 was used as white pig-
ment in tattoos. Similarly, researches from the Centre de re-
cherche et de restauration des musées de France together 
with L’Oréal Research, as well as Argonne National Laborato-
ry, showed that an ancient dyeing process for blacking hair is a 
remarkable illustration of synthetic nanoscale biomineralization. 
And nowadays, nanotechnology is likely to become yet anoth-
er source of potential contamination by unprecedentedly small-
sized inorganic particles.
3.	 Assessing	the	risk	
In order to gauge the engineered NP toxicity risk, it is important 
to analyze existing nanoparticles, and how man and biological 
systems are exposed to extremely fine inorganic matter. Scien-
tific literature is available on cytotoxicity and immunotoxicology 
of metal salts, and the controlled use of their cytotoxicity (as in 
the case of the antineoplastic drug CisPlatin). There is also lit-
erature on the toxicity of micrometric particles (which induce 
granulomatosis). However, little attention has been paid to the 
response of cells to engineered NP despite the fact that now 
we can investigate the subtle interactions and biological rele-
vance of the interplay between inorganic NP and biology. For 
example, it was recently shown that minute clay particles in-
duced order in random coil peptides when attached to the NP 
[[40]. They assumed the form of a helix when connected with 
the negatively charged silica sphere. The complex took on the 
properties of a catalyst, a function similar to that of enzymes in 
living cells [40]. Similarly, it was shown that Au NP could con-
form polypeptide structures into artificial proteins [41]. Summa-
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rizing, the potential cytotoxicity of NP has been attributed to 
their size [42], shape (e.g., needle-like carbon nanotubes [5,6]), 
chemical composition (e.g., heavy metals [43,44]), or surface 
interaction with cells (e.g., the interaction of CdSe/ZnS parti-
cles with cells [45]). Finding information about nanotoxicology 
is complicated by the fact that NP may be called ultrafine parti-
cles by toxicologists [46], Aitken mode and nucleation mode 
particles by atmospheric scientists [47,48], and engineered na-
nostructured materials by materials scientists 
4.	 Nanotechnology	today	
Despite all the above, nanospheres are already used in people. 
Last year, the manufacturing industry spent $30 billion on nan-
otechnology —this is expected to rise to $2.6 trillion by 2014. 
Today, there are almost 400 manufacturer-identified nanotech-
nology-based consumer products on the market, including 
computer chips, automobile parts, clothing, cosmetics, dietary 
supplements, wound dressings, dental-bonding agents, fuel 
cells, tires, optics and electronics [50]. In some of these prod-
ucts (such as skin creams and toothpastes) nanoparticles are 
in direct contact with the human body, and they can continually 
enter the environment by washing off consumer products [51]. 
The National Science Foundation estimates that by 2015 the 
nanotechnology sector will employ more than 2 million workers. 
What has been unclear, or ignored, so far, is that these foreign 
bodies below a certain size can enter animal organisms, mainly 
through ingestion or respiration. They may then interact with the 
gastrointestinal wall, the skin or the pulmonary alveoli, and be 
carried by blood or lymph traveling quite freely through tissues. 
Alternatively, they may settle in tissue they encounter during mi-
gration and thus enter the food chain. Funding for risk-focused 
research is a small -but increasing- fraction of what is spent on 
commercial applications of nanotechnology [52].
Therefore, a number of questions need to be addressed: To 
what extent does the nanoform of a substance have enhanced 
dermal penetration or increased systemic uptake via the lungs 
or gastrointestinal tract? What determines the proportion of NP 
entering into systemic circulation that will be distributed 
throughout the body, reach the bone marrow, cross the 
blood—brain barrier, cross the placenta and affect fetal devel-
opment, or be sequestered effectively in the liver? Do nanopar-
ticles released into the environment affect species that are im-
portant in food chain dynamics? What are the long-term 
consequences of exposure to NP? What are the water solubil-
ity, reactivity (oxidation, agglomeration, corrosion), environ-
ment persistence and environment dispersion of NP? 
5.	 Evaluating	nanotoxicity	
Finally, the numerous studies appearing on NP cytotoxicity, 
such as the study of cell viability after cell cultures are exposed 
to NP, should not be confused with fully-fledged toxicological 
risk assessment. Risk assessments take into account expo-
sure rates, uptake mechanisms, transport within the body, in-
flammation [53], memory and much more. Furthermore, the 
fact that NP are non-toxic for a cell culture within the parame-
ters of a standard cytotoxicity experiment does not mean that 
the NP are non-toxic: they may affect a tissue, disrupting nor-
mal functioning, without significantly or rapidly killing the cells. 
Cytotoxicity studies are usually used as indicators of whether 
more extensive toxicological studies are needed. However, as 
nanotechnology is a new discipline (and due to its interdiscipli-
nary character) the currently available data can be confusing. 
This is often due to the lack of experimental protocols, as in 
the case of optical interference between the nanomaterials 
and cell viability assays. Recently, it was shown how standard 
cell-viability tests may result in “fake” toxicity from carbon na-
notubes [54], and explain why some studies have concluded 
that carbon nanotubes —which are studied for their potential 
to improve building materials, drug-delivery systems, and 
electronics, to name a few applications— are dangerous to 
human health while others have not. The same happens with 
Au NP: Au NP absorb MMT or XTT wavelengths strongly, so 
the optical density measured at these wavelengths will be af-
fected by Au NP absorption [55] and therefore may lead to 
false results [56]. In the simplest case, samples containing NP 
will show more cellular activity than control samples, which 
may mask toxic effects or suggest proliferation powers of the 
NP. The way that NP are prepared, their surface state, the sol-
vent and solutions which carry them, their agglomerated state, 
etc, may all modify results [57,58]. We have also observed that 
chemically identical Au NP - peptide conjugates with different 
surface structures may or may not trigger an immune re-
sponse and inflammation. Furthermore, despite continuing 
encouragement for interdisciplinary collaboration, biological 
applications of objects designed using nanotechnology still 
suffer from a lack of interdisciplinary coordination. Chemists, 
physicists, and engineers create new advanced materials with 
sophisticated functionalities on a daily basis, but their under-
standing of biology is usually limited. This leads to straightfor-
ward uptake of nanoparticles being studied, while whether the 
incorporated particles are stuck in endosomal/lysosomal 
structures or free in the cytoplasm is ignored. Biologists typi-
cally study the uptake of NP by cells using relatively undefined 
nanoparticles with large polydispersity, limited colloidal stabili-
ty, unknown surface chemistry, etc. And finally, the social as-
pect of toxicity makes it difficult to extract conclusions, and 
results (even the more technical ones) are often biased to-
wards toxicity or non-toxicity depending on the context of the 
report, e.g., presenting a new medical device versus evaluat-
ing the toxicity of a material.
6.	 Regulation	and	social	impact	of	
nanotechnology	
Regulation and social impact are normally overlooked by scien-
tists, but the world does not change because of the introduc-
tion of a new technology on its own. Technology gets intro-
duced into social networks and therefore the applications that 
develop are a mix of social and technological forces. If society 
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embraces and finds uses for a technology then it survives, if we 
do not, then no matter how good the technology is, it will die. 
Nowadays, some may believe that engineered NP are so risky 
that they call for a precautionary halt in NP-related research. 
However, the precautionary principle should not be used to 
stop research related to nanotechnology and NP, but uncon-
trolled industrial uses. A major environmental or health and 
safety problem—whether real or not—involving a product or 
application labeled as ‘nanotechnology’—whether it actually is 
nanotechnology or not—could dampen public confidence and 
investment in nanotechnology. It may even lead to unwise reg-
ulation. At this point, adequate governmental regulation is diffi-
cult given the lack of data on engineered NP and risk assess-
ment. Efforts are being made by the American National 
Standards Institute (ANSI) and by the International Council on 
Nanotechnology (ICON, a coalition of academic, industrial, 
governmental and //civil society organizations), as well as the 
International Organization for Standardization (ISO, Geneva, 
Switzerland). These associations are collecting data to aid un-
derstanding and regulation of nanotechnology. In parallel, in-
ternational non-governmental ecological, environmental, labor 
and biocentric associations have very recently teamed up to 
issue a list of recommendations to avoid nanotechnology poi-
soning [59].Their concerns are not only about consumer and 
worker health and safety but also about the social and ethical 
implications of socio-economic issues (related to weak econo-
mies in developing countries and patents). We hope that in the 
near future, governmental and non-governmental organiza-
tions will work together to assess risks and introduce nanote-
chnology into society. We also hope that these concerns re-
garding health and the environment will be extended to other 
human activities, leading to responsible and rational use, and 
sustainability, not just of nanotechnology which is in fashion.
Apart from these governmental, academic and civil associa-
tions, products and companies are evolving rapidly, increasing 
the number of products (such as nanokeratine) and their nan-
otechnological quality. 
7.	 Nanosilver:	a	case	study	
A paradigmatic case of recent regulation is nanosilver. The un-
controlled use of nanosilver is being banned in the US and it will 
soon also be banned in Europe and probably the rest of the 
world. The US Environmental Protection Agency (EPA) took its 
first step to regulate a nanomaterial, nanosilver, silver NP being 
used as a pesticide [60]. Nanosilver is found as a pesticide in 
several dozen products, including socks and shoes, and plas-
tic storage containers. It prevents fungal and bacterial growth. 
However, the EPA was targeting a washing machine[yes I am], 
built by a major manufacturer, which releases nano-engineered 
silver ions into the wash cycle to kill bacteria. The silver would 
clearly flow into the environment. It is clear that the uncontrolled 
dispersion of persistent bactericide NPs in the environment or 
in the body presents a risk. Colloidal silver is not deactivated 
after killing the bacteria (as penicillin would be, for example). It 
is a catalyst, and therefore highly persistent and active until it 
agglomerates or is subsumed into a body that results in its de-
activation. Nanosilver attaches to the cell membrane creating 
lethal pores and producing bacteria lysis. Silver in its macro-
scopic form is already known to damage aquatic organisms.
8.	 Conclusions	
Apart from industrial uses of materials and commodities, which 
can be delayed until full risk assessment is carried out, the spe-
cial interaction of NP with organisms means that inorganic en-
gineered NP are also at the heart of the development of nano-
biomedical robots. As mentioned, the most important impact 
of the new nanometric revolution will not come from materials 
science but from life science [61]. Therefore, if we are to start 
introducing tiny foreign bodies into people for diagnosis and 
therapy, knowledge of the specific interactions with the system 
has to be deep and extensive. A significant effort must be 
made in the coming years to resolve such questions, since in-
teraction with living organisms is difficult and often unpredicta-
ble. The balance of positive and negative consequences of the 
interaction of NP with people can be illustrated by the example 
of iron oxide. It has been suggested that it is useful as a hyper-
thermia agent for cancer treatment in places, such as the brain, 
where surgery is not an option, or as an MRI contrast agent. It 
is also used as a drug for iron administration in cases of ane-
mia. Recently iron oxide was found to be concomitant with 
Alzheimer’s disease [62,63] with size and composition which 
excludes its ferritine origin. In addition, it was recently reported 
that iron dextran administrated to mice was dissolved in the 
liver and transformed into other iron deposits showing the me-
tabolism of iron oxide NP [64,65]. In fact, the toxicity of super-
paramagnetic iron oxide NP has been the focus of research for 
a long time [66-68] but reports of potential medical benefits 
continue to appear constantly, together, of course, with those 
concerning its toxicity. Thus, while some find new promise for 
nerve cell regeneration [69], others detect the toxic effect of 
this material on neuronal cells [70] and so on. In the end, both 
the potential toxic and potential beneficial effects will coexist. 
Therefore, looking at these data, one will have to carefully de-
cide about a prolonged treatment of young patients for anemia 
with iron NP which could alter iron metabolism in the brain and, 
in the future, lead to neurodegeneration. While if the patient, of 
any age, has a terminal cancer, should he/she care about Par-
kinson’s or Alzheimer’s disease decades later compared to 
surviving the coming months? 
Nowadays, many people believe nanotechnology will be the 
key to solving many of the world’s most pressing medical 
problems, while others believe it could lead to a potential disas-
ter [71]. There is, therefore, a profusion of opinions, including 
those in prestigious scientific journals [52,72-74] where a ra-
tional approach based on common sense is called for. It is 
clear that we can cope [75] and that the approach to risk as-
sessment has to be comprehensive, including dose, time, 
memory, damage, cancer, etc. Fortunately, inorganic NP nor-
mally have signatures which allow them to be monitored in or-
ganic/biological environments. Thus, it is likely that at the same 
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time that we see NP and carbon nanostructures used in con-
trolled medical applications, restrictive regulations will appear 
to control the dispersion of these new chemicals. What we can 
already say is that each NP is different (size, shape, composi-
tion, surface, etc.) and therefore so is its toxicity, and it will be 
difficult to define generic nanotoxicity. 
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